FindTrial
Sign In

A study to understand the financial burden that Duchenne Muscular Dystrophy as a disease imposes

The economic burden of Duchenne Muscular Dystrophy at a public health tertiary care hospital in Mumbai

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/01/049168
Enrollment
60
Registered
2023-01-24
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G710- Muscular dystrophy

Interventions

None listed

Sponsors

Dr Mamta Muranjan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed DMD, with or without genetic confirmation.

Exclusion criteria

Exclusion criteria: Patients not willing to give consent for participation.

Design outcomes

Primary

MeasureTime frame
To study the economic burden of Duchenne Muscular Dystrophy (DMD) in terms of cost to the family and the health care system from a societal perspective. To estimate the national burden of DMD using country specific prevalence rates Timepoint: Baseline—

Secondary

MeasureTime frame
We also aim to determine factors impacting economic burden of DMD in terms of age of onset, duration and stage of disease, socioeconomic status of family and other variables. Timepoint: Baseline—

Countries

India

Contacts

Public ContactSonu Antony

Seth GS Medical College and KEM Hospital

muranjanmamta@rediffmail.com9920209036

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026